Oppenheimer Issues a Buy Rating on Incyte (INCY)


In a report released today, Jay Olson from Oppenheimer assigned a Buy rating to Incyte (INCY), with a price target of $120.00. The company’s shares closed last Monday at $92.19.

According to TipRanks.com, Olson ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.9% and a 36.9% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on Incyte is a Moderate Buy with an average price target of $100.71, representing an 11.3% upside. In a report issued on June 4, Argus Research also maintained a Buy rating on the stock with a $124.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $104.81 and a one-year low of $62.48. Currently, Incyte has an average volume of 1.92M.

Based on the recent corporate insider activity of 132 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INCY in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Read More on INCY:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts